Skip to main content


Catalan CRO (Contract Research Organization) Kymos Pharma Services has reached an agreement with French biotechnology group Ipsen to take on a team of eight scientists from Ipsen’s R&D center in Sant Feliu de Llobregat (Barcelona). Ipsen devotes 20% of its turnover (some €1,100 millions) to R&D. Before the end of the year, the company expects to close its Sant Feliu center.

For Kymos —which is based in the Barcelona Science Park (PCB) and is celebrating its tenth anniversary this year— this means creating an innovative R&D area in the field of biomolecules and biosimilars. The company will carry out this activity with a new immunological laboratory that will be inaugurated in the BSP in January with the aim of carrying out regulatory development projects for biotechnology companies.

“This new partnership consolidates our growth plan as well as our international expansion plans, as it makes us the only CRO in Spain, and one of the few in Europe, to provide integral scientific/technical services for biotechnology companies in line with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP),” explains Kymos General Manager Joan Puig de Dou.

Kymos currently focuses on integral analytic development for the pharmaceutical, veterinary and related sectors, as well as bioanalysis of pre-clinical and clinical studies, mainly in the field of small molecules. The company’s turnover totals more than €2.5 millions, it has a staff of 35 professionals and direct presence in Portugal and Italy.

Sign up for our newsletters

Stay up-to-date on the latest news, events and trends in the BioRegion.